amycretin novo nordisk - Search News

Novo Nordisk, amycretin obesity drug

Investopedia on MSN · 6h

Novo Nordisk Stock Jumps on Early Stage Weight-Loss Drug Trial Results

Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for its amycretin weight-loss drug.

Novo Nordisk reports 22% weight loss in early subcutaneous amycretin trial

Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying people with obesity or overweight treated with the drug achieved a 22% weight loss after 36 weeks.

Hosted on MSN · 6h

Ozempic maker’s stock surges. A trial of a new Novo Nordisk drug shows promise.

Novo Nordisk shares jumped on Friday as the Danish drugmaker said an experimental drug was able to reduce weight by as much as 22%.

Novo Nordisk’s next-generation obesity treatment shows promise in early study

A new weight loss drug from Novo Nordisk helped patients lose a large amount of weight, providing a boost for Novo in the ...

7h

Novo Nordisk amycretin data helps rebut concerns, says BofA

After Novo Nordisk (NVO) reported that subcutaneous amycretin demonstrated up to 22% absolute weight loss at 36-weeks in a Phase 1/2a trial, ...

6hon MSN

Novo Nordisk stock pops on Phase 1 data for new weight loss drug amycretin

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results